Advertisement

Exploring the factors associated with lipohypertrophy in insulin-treated type 2 diabetes patients in a tertiary care hospital in Mumbai, India

  • Vimal Pahuja
  • Pankaj Punjot
  • Genevie Fernandes
  • Nilesh ChatterjeeEmail author
Original Article
  • 20 Downloads

Abstract

Background

This exploratory study reports the prevalence of lipohypertrophy (LH) in insulin-treated type 2 diabetes patients attending a private tertiary hospital in Mumbai, India, and explores the factors associated with this condition.

Methods

A total of 96 patients attending the outpatient department, completed an interviewer-administered questionnaire followed by an examination of insulin injection sites for the presence of LH by a trained diabetes nurse educator.

Results

Nearly 68% of the respondents had LH. Most patients (82%) had LH on at least two injection sites, with the frontal areas of the right and left side of the abdomen being the most common sites. Despite a high prevalence of LH, the majority of patients were unaware that they had the condition (77%) and could not identify the causes (74%). Half of the patients reported awareness about the different sites for injecting insulin, injection techniques, and the need for rotating injection sites. Only 26% always rotated injection sites, while 16% changed needles more than half of the time in the week prior to the interview. Bivariate analysis found higher number of years with diabetes and on insulin and a higher insulin dose per day as significant factors (p value < 0.05). Logistic regression showed a strong relationship between the presence of LH and the number of years on insulin (p value < 0.05). The number of years on insulin for patients with and without LH averaged 8.2 and 3.7, respectively.

Conclusion

Findings highlight a gap in patients’ knowledge and management of LH, and call for a hospital-wide intervention encompassing patient education and provider sensitization.

Keywords

Lipohypertrophy Insulin complication Type 2 diabetes Urban India 

Notes

Acknowledgements

We also thank the management of Dr. L.H. Hiranandani Hospital, Powai for permission to conduct the study and the doctors, nurses, and research staff for their support in the data collection process in the inpatient wards. Thanks also go to Shirlly Koshy for data management. Most importantly, we are grateful to the patients who freely gave their time and inputs.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors. The study was approved by the Ethics Committee of Dr. L.H. Hiranandani Hospital, Mumbai.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    International Diabetes Federation (IDF). IDF Atlas 8th Edition. Brussels: IDF; 2017.Google Scholar
  2. 2.
    Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.CrossRefGoogle Scholar
  3. 3.
    Cunningham MT, McKenna M. Lipohypertrophy in insulin treated diabetes: prevalence and associated risk factors. J Diabetes Nurs. 2013;17:340–3.Google Scholar
  4. 4.
    Kalra S, Mithal A, Sahay R, John M, Unnikrishnan AG, Saboo B, et al. Indian injection technique study: population characteristics and injection practices. Diabetes Ther. 2017;8:637–57.CrossRefGoogle Scholar
  5. 5.
    Sharma A, Kaplan WA. Challenges constraining access to insulin in the private-sector market of Delhi, India. BMJ Glob Health. 2016;1:e000112.CrossRefGoogle Scholar
  6. 6.
    Blanco M, Hernandez MT, Strauss KW, et al. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013;39:445–53.CrossRefGoogle Scholar
  7. 7.
    Richardson T, Kerr D. Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am J Clin Dermatol. 2003;4:661–7.CrossRefGoogle Scholar
  8. 8.
    Teft G. Lipohypertrophy: patient awareness and implications for practice – clinical audit. J Diabetes Nurs. 2002;6:20–3.Google Scholar
  9. 9.
    Johansson U-B, Amsberg S, Hannerz L, Wredling R, Adamson U, Arnqvist HJ, et al. Impaired absorption of insulin as part from lipohypertrophic injection sites. Diabetes Care. 2005;28:2025–7.CrossRefGoogle Scholar
  10. 10.
    Smith KJ, Rabasa-Lhoret R, Strychar I, Karelis AD, Clyde M, Levasseur J, et al. Good vs. poor self-rated diabetes control: differences in cardiovascular risk and self-care activities. Exp Clin Endocrinol Diabetes. 2014;122:236–9.CrossRefGoogle Scholar
  11. 11.
    Noor S, Khan RU, Ahmad J. Understanding diabetic foot infection and its management. Diabetes Metab Syndr. 2017;11:149–56.CrossRefGoogle Scholar
  12. 12.
    Mowatt L. Diabetic retinopathy and its risk factors at the University Hospital in Jamaica. Middle East Afr J Ophthalmol. 2013;20:321–6.CrossRefGoogle Scholar
  13. 13.
    Boer IHD, Group FE. Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37:24–30.CrossRefGoogle Scholar
  14. 14.
    Ji L, Sun Z, Li Q, Qin G, Wei Z, Liu J, et al. Lipohypertrophy in China: prevalence, risk factors, insulin consumption, and clinical impact. Diabetes Technol Ther. 2017;19:61–7.CrossRefGoogle Scholar
  15. 15.
    Deng N, Zhang X, Zhao F, Wang Y, He H. Prevalence of lipohypertrophy in insulin-treated diabetes patients: a systematic review and meta-analysis. J Diabetes Investig. 2018;9:536–43.CrossRefGoogle Scholar
  16. 16.
    Li FF, Fu SM, Liu ZP, et al. Injection sites lipohypertrophy among 736 patients with type 2 diabetes of different-grade hospitals. Int J Clin Exp Med. 2016;9:13178–83.Google Scholar
  17. 17.
    Pavlovic MD, Milenkovic T, Dinic M, Misovic M, Dakovic D, Todorovic S, et al. The prevalence of cutaneous manifestations in young patients with Type 1 diabetes. Diabetes Care. 2007;30:1964–7.CrossRefGoogle Scholar
  18. 18.
    Baruah M, Kalra S, Bose S, Deka J. An audit of insulin usage and insulin injection practices in a large Indian cohort. Indian J Endocrinol Metab. 2017;21:443–52.CrossRefGoogle Scholar
  19. 19.
    Patil M, Sahoo J, Kamalanathan S, et al. Assessment of insulin injection techniques among diabetes patients in a tertiary care Centre. Diabetes Metab Syndr. 2016;11:S53–6.CrossRefGoogle Scholar
  20. 20.
    Sawatkar GU, Kanwar AJ, Dogra S, Bhadada SK, Dayal D. Spectrum of cutaneous manifestations of type 1 diabetes mellitus in 500 South Asian patients. Br J Dermatol. 2014;171:1402–6.CrossRefGoogle Scholar
  21. 21.
    Green S. How many subjects does it take to do a regression analysis. Multivar Behav Res. 1991;26:499–510.CrossRefGoogle Scholar
  22. 22.
    Vardar B, Kizilci S. Incidence of lipohypertrophy in diabetic patients and a study of influencing factors. Diabetes Res Clin Pract. 2007;77:231–6.CrossRefGoogle Scholar
  23. 23.
    Strauss K, Gols H, Hannet I, Partanen TM, Frid A. A Pan European epidemiologic study of insulin injection technique in patients with diabetes. Pract Diab Int. 2002;19:71–6.CrossRefGoogle Scholar
  24. 24.
    Hauner H, Stockamp B, Haastert B. Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Exp Clin Endocrinol Diabetes. 1996;104:106–10.CrossRefGoogle Scholar
  25. 25.
    Frid A, Hirsch L, Menchior A, Morel DR, Strauss KW. Worldwide Injection Technique Questionnaire Study: Population Parameters and Injection Practices. Mayo Clin Proc. 2016;91:1212–23.CrossRefGoogle Scholar
  26. 26.
    De Villiers FP. Lipohypertrophy – a complication of insulin injections. S Afr Med J. 2005;95:858–9.Google Scholar
  27. 27.
    Hambridge K. The management of lipohypertrophy in diabetes care. Br J Nurs. 2007;16:520–4.CrossRefGoogle Scholar
  28. 28.
    Grassi G, Scuntero P, Trepiccioni R, Marubbi F, Strauss K. Optimizing insulin injection technique and its effect on blood glucose control. J Clin Transl Endocrinol. 2014;1:145–50.Google Scholar
  29. 29.
    Strauss G, De Gols H, Letondeur C, Matyjaszczyk M, et al. Report of the second injection technique event (SITE), May 2000, Barcelona, Spain. Conference report. Pract Diabetes Int. 2000;19:17–21.CrossRefGoogle Scholar
  30. 30.
    Gentile S, Guarino G, Giancaterini A, et al. A suitable palpation technique allows to identify skin lipohypertrophic lesions in insulin-treated people with diabetes. Springer Plus. 2016;5:563.CrossRefGoogle Scholar

Copyright information

© Research Society for Study of Diabetes in India 2019

Authors and Affiliations

  1. 1.Obesity and Diabetes Center of ExcellenceDr. L.H. Hiranandani HospitalMumbaiIndia
  2. 2.Dr. L.H. Hiranandani HospitalMumbaiIndia
  3. 3.Usher Institute of Population Health Sciences and InformaticsUniversity of EdinburghEdinburghScotland
  4. 4.Kalyani Media GroupMumbaiIndia

Personalised recommendations